



**Report of Voting Results  
Medicenna Therapeutics Corp.**

In accordance with Section 11.3 of National Instrument 51-102, the following describes the matters voted upon and the outcome of the votes at the annual general meeting of shareholders of Medicenna Therapeutics Corp. (the "Corporation") held virtually on September 26, 2024.

1. Based on the proxies received and the votes by ballot, each of the nominees for election as directors was elected to hold office until the next annual meeting of shareholders or until such director resigns or a successor is elected or appointed.

Proxies received and votes by ballot at the meeting were as follows:

<b>Nominee</b>	<b>Votes For</b>	<b>% of Votes For</b>	<b>Votes Against</b>	<b>% of Votes Against</b>
Dr. Fahar Merchant	26,237,107	99.44%	148,557	0.56%
Mr. Albert Beraldo	26,325,950	99.77%	59,714	0.23%
Dr. John (Jack) Geltosky	26,190,452	99.26%	195,212	0.74%
Ms. Karen Dawes	26,228,732	99.41%	156,932	0.59%
Dr. John Sampson	20,428,706	77.42%	5,956,958	22.58%
Mr. Karim Lalji	26,314,082	99.73%	71,582	0.27%

2. Based on the proxies received and the votes by ballot, MNP LLP was appointed as auditor of the Corporation to hold office until the next annual meeting or until its successor is appointed, and the directors were authorized to fix its remuneration. Approximately 99.49% of the proxies received and represented at the meeting were voted in favour of the appointment and approximately 0.51% of the proxies received and represented at the meeting were withheld from voting.

In total, approximately 45.89% of the issued and outstanding shares were represented in person or by proxy at the meeting.

Yours very truly,

/s/ David Hyman  
Chief Financial Officer